Qure Ventures
Qure Ventures is a venture capital firm based in Herzliya, Israel, founded in 2012. It is notable for being Israel's first fund exclusively focused on digital health. The firm is led by experienced professionals from the digital health sector who have a track record of founding, growing, and exiting companies over the past two decades. Qure Ventures primarily invests in startups located in Israel, leveraging the country's prominent tech and digital health ecosystem. The firm has established strategic partnerships with key stakeholders across various domains, including consumers, providers, payers, and pharmaceuticals, which facilitates rapid access to market and clinical trial opportunities for its portfolio companies. Additionally, Qure Ventures benefits from the global network and medical expertise of its parent company, OurCrowd, enhancing its deal access and due diligence capabilities.
Past deals in Vermont
CoreMap
Series B in 2022
CoreMap, Inc. is a medical technology company based in Winooski, Vermont, focused on developing advanced diagnostic solutions for electrophysiologists treating atrial fibrillation. Incorporated in 2016, the company offers a micro-electrode solution that allows for sequential mapping of tissue properties, addressing significant challenges in the treatment of atrial fibrillation, such as poor spatial resolution and inadequate sample density. Additionally, CoreMap's ultra-high resolution electrodes provide detailed insights into cardiac activation, even during episodes of fibrillation. By enhancing the diagnostic capabilities of electrophysiologists, CoreMap aims to improve patient outcomes in the management of this complex condition.
CoreMap
Series A in 2020
CoreMap, Inc. is a medical technology company based in Winooski, Vermont, focused on developing advanced diagnostic solutions for electrophysiologists treating atrial fibrillation. Incorporated in 2016, the company offers a micro-electrode solution that allows for sequential mapping of tissue properties, addressing significant challenges in the treatment of atrial fibrillation, such as poor spatial resolution and inadequate sample density. Additionally, CoreMap's ultra-high resolution electrodes provide detailed insights into cardiac activation, even during episodes of fibrillation. By enhancing the diagnostic capabilities of electrophysiologists, CoreMap aims to improve patient outcomes in the management of this complex condition.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.